

# First synthesis of cyclotrihydrazino peptides

Sophie Carret, Michèle Baudy-Floc'h, Albert Robert and Philippe Le Grel\*

Groupe de Recherches Synthèse et Electrosynthèse Organiques Université de Rennes I, UMR CNRS 6510 Avenue du Général Leclerc, F-35042 Rennes Cédex, France

## Synthesis of novel cyclotrihydrazino peptides using an original cyclisation method at high dilution.

A growing number of peptides are regularly isolated from animal and human tissues. Most exhibit interesting biological effects as hormones or neuromediators. From this point of view they appear to possess high potential as therapeutic agents. However, among other reasons, their low bioavailability represents a strong limitation on their use in this field. To solve this problem peptide analogues have been synthesised and screened to produce active peptidomimetic compounds with enhanced enzyme resistance.<sup>1</sup> Among them, pseudo-peptides, in which the peptidic linkage is modified, are the object of great interest and have already lead to some concrete applications. For example 'Zoladex' is a powerful anticancer drug in the azapeptide class.<sup>2</sup>

Peptidase action is also generally lower on cyclic peptides and some, like Bortromycin, have found good use as antibiotics.<sup>3</sup> However, obtaining cyclic derivatives remains a problematic aspect of peptidic synthesis; yields are generally low and various factors influence the success or failure of cyclisation, including the nature and the connections of amino acid residues, solvent effects, concentration and also the type of reaction involved to induce ring closure.<sup>4,5</sup>


Here we report preliminary results of the synthesis of, to the best of our knowledge, the first cyclotrihydrazino peptides. The linear precursors were prepared using improvements to a methodology that we have already described in a previous paper.<sup>6</sup> To achieve the ring closure we perfected an original strategy which supplements classical methods of peptide cyclisation such as azide activation,<sup>7</sup> activated esters<sup>8</sup> or coupling reagents.<sup>9</sup> Scheme 1 summarizes the synthesis. Reacting *gem*-dicyano epoxides **1** with Bu<sup>t</sup>CO<sub>2</sub>NHNH<sub>2</sub>·HBr leads to  $\alpha$ -halo hydrazides **2**.<sup>11</sup> Substitution of the halogen by methylhydrazine gives **3** which is then acylated by chloroacetyl chloride to afford **4**. Reiteration of these two steps gives **6** which includes a terminal azaglycine ester linked to an aryl hydrazino-sarcosine, itself connected to an *N*-chloroacetylated hydrazino-sarcosine.

We took advantage of the high lability of the halogen atom in  $\alpha$ -halo hydrazides. Indeed, we have shown that such halogens are easily displaced by nucleophiles when the reaction takes place in the presence of an additional base.<sup>12</sup> After elimination of the Boc function we get the polyhalo compound **7** (with undetermined HCl stoichiometry); this was then treated in high dilution in MeCN with pyridine (5 equiv.). Cyclotrihydrazino peptide **8** precipitated slowly as an amorphous powder (20% yield after purification). Compound **8** was characterized by <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy, and its monomeric structure was established by FAB mass spectroscopy (formation of the cyclodimer had to be ruled out). Microanalysis confirmed the high purity of the compound.† At the time we undertook this work, Gani used a similar method to synthesise 1,2,5-triazepine-3,6-diones.<sup>13</sup>

It has been shown by X-ray and model studies that hydrazino acid residues can stabilize the folded conformation of small pseudo-peptidic patterns by hydrogen bonding.<sup>14</sup> The success of our synthesis of pseudo-peptide **8** may arise from such a

favourable conformation bringing nearer the two reactive ends (Fig. 1).

It is worth noting that despite the high solubility of **7** and the insolubility of **8** in water, this solvent failed to allow cyclisation, possibly because competitive hydrogen bonding with water



**Scheme 1** Reagents and conditions (for R = *p*-ClC<sub>6</sub>H<sub>4</sub>): i, Bu<sup>t</sup>CO<sub>2</sub>NHNH<sub>2</sub>·HBr, MeCN, room temp., 8 h, 99%; ii, NH<sub>2</sub>NHMe, MeCN, 0 °C, 2 h, 93%; iii, ClCH<sub>2</sub>COCl, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 84%; iv, HCl (g), CH<sub>2</sub>Cl<sub>2</sub>, 5 min., room temp., 99%; v, pyridine, MeCN, room temp. 2 d, 20%




Fig. 1

destroys the favourable conformation for closure. This result emphasizes the crucial role played by the solvent in determining the precursor's geometry.

This preliminary work opens the way to the preparation of other original cyclopeptide-peptides of smaller or larger size, with different arrangements and various side chains. We also plan to investigate solvent effects in more detail; in particular we will examine the influence of adding ions to the reactions carried out in water.

### Footnotes

\* E-mail: michele.baudy-floch@univ-rennes1.fr

† Selected data for **8a**: 20%; mp > 260 °C; <sup>1</sup>H NMR (200 MHz, D<sub>2</sub>O–CF<sub>3</sub>CO<sub>2</sub>H) 2.24 (s, 3 H), 2.58 (s, 3 H), 3.27 (m, 2 H), 3.36 (m, 2 H), 4.24 (s, 1 H), 7.37 (m, 4 H); <sup>13</sup>C NMR (200 MHz, D<sub>2</sub>O–[<sup>2</sup>H<sub>6</sub>]DMSO) 43 (q, *J* 142 Hz), 44 (q, *J* 142 Hz), 53 (t, *J* 147 Hz), 59 (t, *J* 150 Hz), 70 (d, *J* 142 Hz), 128.5 (d, *J* 168 Hz), 129 (d, *J* 168 Hz), 132, 135, 166, 168, 172; ν<sub>max</sub> (Nujol)/cm<sup>-1</sup> 3290, 3240 br (NH), 1700, 1650, 1620 br (CO); HRMS (FAB) (MH<sup>+</sup>) Calc. for C<sub>14</sub>H<sub>20</sub>N<sub>6</sub>O<sub>3</sub>Cl: 355.1284. Found: 355.1263. Calc.: C, 47.39; H, 5.40; N, 23.69; Cl, 9.90. Found: C, 47.45; H, 5.36; N, 23.66; Cl, 10.00%.

### References

1 A. Giannis and T. Kolter, *Angew. Chem., Int. Ed. Engl.*, 1993, **32**, 1244.

- 2 J. Gante, *Synthesis*, 1989, 405.
- 3 Y. A. Ovchinnikov and V. T. Ivanov, *Tetrahedron*, 1989, **31**, 2177.
- 4 M. Bodanszky, *Principles of Peptide Synthesis*, Springer Verlag, 1984.
- 5 K. D. Kopple, *J. Pharm. Sci.*, 1972, **61**, 1345.
- 6 C. Barré, P. Le Grel, A. Robert and M. Baudy-Floc'h, *J. Chem. Soc., Chem. Commun.*, 1994, 607.
- 7 Y. S. Klausner and M. Bodansky, *Synthesis*, 1974, 549.
- 8 M. Waki and N. Izumiyia, *J. Am. Chem. Soc.*, 1967, **89**, 1278.
- 9 R. Paul and G. W. Anderson, *J. Am. Chem. Soc.*, 1960, **82**, 4596; B. Neises and W. Steglich, *Angew. Chem., Int. Ed. Engl.*, 1978, **17**, 522; B. Castro, J. R. Dormoy, G. Evin and C. Selve, *Tetrahedron Lett.*, 1975, 1219; R. Knorr, A. Trzeciak, W. Bannwarth and D. Gillessen, *Tetrahedron Lett.*, 1989, **30**, 1927.
- 10 Epoxides **1** were prepared in a two step procedure. For the first one, a Knoevenagel–Cope condensation, see P. D. Gardner and R. L. Brandon, *J. Org. Chem.*, 1957, **22**, 1704. For the second step, a stereospecific epoxidation of the alkene by sodium hypochlorite, see M. Baudy, A. Robert and A. Foucaud, *J. Org. Chem.*, 1978, **43**, 3732.
- 11 P. Le Grel, M. Baudy-Floc'h and A. Robert, *Synthesis*, 1987, 306.
- 12 P. LeGrel, M. Baudy-Floc'h and A. Robert, *Tetrahedron*, 1988, **44**, 4805.
- 13 M. M. Lenman, S. L. Ingham and D. Gani, *Chem. Commun.*, 1996, 85.
- 14 M. Marraud, V. Dupont, V. Grand, S. Zerkout, A. Lecoq, G. Boussard, J. Vidal, A. Collet and A. Aubry, *Biopolymers*, 1993, **33**, 1135.

Received in Glasgow, UK, 6th February 1997; 7/01932G